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Cleveland, Ohio
Objectives This study was designed to examine the safety and efficacy of sodium nitroprusside (SNP) for patients with
acute decompensated heart failure (ADHF) and low-output states.
Background Inotropic therapy has been predominantly used in the management of patients with ADHF presenting with low
cardiac output.
Methods We reviewed all consecutive patients with ADHF admitted between 2000 and 2005 with a cardiac index 2
l/min/m2 for intensive medical therapy including vasoactive drugs. Administration of SNP was chosen by the
attending clinician, nonrandomized, and titrated to a target mean arterial pressure of 65 to 70 mm Hg.
Results Compared with control patients (n  97), cases treated with SNP (n  78) had significantly higher mean central
venous pressure (15 vs. 13 mm Hg; p  0.001), pulmonary capillary wedge pressure (29 vs. 24 mm Hg; p 
0.001), but similar demographics, medications, and renal function at baseline. Use of SNP was not associated
with higher rates of inotropic support or worsening renal function during hospitalization. Patients treated with
SNP achieved greater improvement in hemodynamic measurements during hospitalization, had higher rates of
oral vasodilator prescription at discharge, and had lower rates of all-cause mortality (29% vs. 44%; odds ratio:
0.48; p  0.005; 95% confidence interval: 0.29 to 0.80) without increase in rehospitalization rates (58% vs.
56%; p  NS).
Conclusions In patients with advanced, low-output heart failure, vasodilator therapy used in conjunction with optimal current
medical therapy during hospitalization might be associated with favorable long-term clinical outcomes irrespec-
tive of inotropic support or renal dysfunction and remains an excellent therapeutic choice in hospitalized ADHF
patients. (J Am Coll Cardiol 2008;52:200–7) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.02.083p
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pdvances in medical therapies (such as neurohormonal
odulation and pacing/defibrillation strategies) have signif-
cantly altered the natural history of heart failure and
mproved long-term outcomes (1–5). However, the patho-
hysiology and treatment of acute decompensated heart
ailure (ADHF) remains poorly understood, especially in
ore advanced stages when cardiac output is significantly
educed. Our treatment goal remains symptomatic relief,
rimarily by decreasing volume overload and attenuating
ulmonary congestion with loop diuretics. In the setting of
low cardiac output, augmentation of contractility with
arenteral inotropic therapy is often used. However, vaso-
ctive drugs are often administered at the expense of a
rom the Department of Cardiovascular Medicine, Kaufman Center for Heart
ailure, Cleveland Clinic, Cleveland, Ohio. The authors had full access to the data
nd take responsibility for its integrity. All authors have read and agree to the article
s written.
Manuscript received November 15, 2007; revised manuscript received February 7,
008, accepted February 12, 2008.otential risk of developing adverse outcomes including
orsening renal function or precipitating arrhythmias
6–8). Concern has also arisen from post hoc observations
hat short-term infusions of newer drugs such as levosimen-
an, milrinone, and nesiritide in hospitalized ADHF pa-
ients might negatively impact long-term outcomes (9–11).
See page 208
There is a resurgence of interest in the use of intravenous
asodilators in the management of ADHF, particularly with
he recognition that a large majority of patients present with
levated rather than low blood pressures (12). The latest
linical guidelines from the Heart Failure Society of America
13) advocate the use of intravenous vasodilators as part of the
reatment strategy for ADHF (Level of Evidence: C). Despite
hese guideline recommendations, only about 18% of all
atients hospitalized for ADHF received these agents and
1% received sodium nitroprusside (SNP) (14).
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July 15, 2008:200–7 Vasodilators for Low-Output Heart FailureSodium nitroprusside is an older intravenous vasodilator,
hich is often being used to titrate off inotropic therapy in
atients with refractory heart failure (15). It is administered
lmost exclusively in critical care settings with careful
nvasive hemodynamic monitoring due to the risk of
nducing hypotension. Furthermore, prolonged use of
NP has been associated with the risk of thiocyanate
oxicity. These concerns have hindered the general enthu-
iasm in using SNP in the contemporary management of
DHF, even though the favorable hemodynamic effects
ave been well-documented.
Based on our extensive experience with SNP over many
ears in a heart failure intensive care unit, the primary aim
f this study was to examine the safety and efficacy of a
asodilator such as SNP as part of the treatment regimen for
ospitalized ADHF patients with low-output states. An
mportant objective was to characterize the group selected to
eceive SNP, compare it with those patients treated with
lternative strategies, and determine whether there were
ny short- and long-term differences in treatment pat-
erns and clinical outcomes between the 2 groups. There
re no similar data currently available in the contempo-
ary literature.
ethods
atient population. We reviewed the electronic medical
ecords of consecutive patients, age 18 years, with
hronic (6 months) systolic heart failure (New York
eart Association functional class III to IV), who un-
erwent a right heart catheterization for evaluation of
DHF at the Cleveland Clinic between January 1, 2000,
nd December 31, 2005. From this large cohort, we
arrowed our study population to include only patients
ctually admitted to the heart failure intensive care unit
or intensive medical therapy (15). The inclusion criteria
ncluded: 1) impaired cardiac output defined by cardiac
ndex 2.0 l/min/m2; and 2) elevated filling pressures, as
efined by pulmonary capillary wedge pressure (PCWP)
18 mm Hg and/or right atrial pressure 8 mm Hg.
xclusion criteria included: 1) use of inotropic infusion at
he time of cardiac catheterization; 2) use of nesiritide
uring admission; and 3) mean systemic arterial pressure
MAP) 60 mm Hg at the time of cardiac catheteriza-
ion. The Cleveland Clinic Institutional Review Board
pproved this project.
rotocol for intensive medical therapy. The pharmaco-
ogic approach and hemodynamic goals of intravenous therapy
or ADHF have been previously described (16). Briefly, opti-
al hemodynamic response is defined as a decrease in PCWP
o18 mm Hg, decrease in mean pulmonary arterial pressure
mPAP) by at least 20%, decrease in right atrial pressure to8
mHg, and improvement in cardiac index to2.2 l/min/m2,
ll while maintaining MAP65 mmHg. The systemic blood
ressure was generally measured noninvasively by an automatic
uff sphygmomanometer every 15 min. To achieve the hemo- rynamic goals, most patients
ere treated with simultaneous
ntravenous diuretics in combi-
ation with either vasodilators or
notropic agents while continu-
ng previous therapies with
ngiotensin-converting enzyme
nhibitors or angiotensin-receptor
lockers, beta-adrenergic blockers,
ydralazine, isosorbide dinitrate,
nd spironolactone as tolerated.
ome patients received both SNP
nd inotropic drugs, and for pur-
oses of this analysis, they are con-
idered in the SNP group.
NP infusion protocol. The
ecision to use SNP and/or inotropic therapy was at the
iscretion of the physician caring for the patient and no
andomization scheme was employed. In addition, there
ight have been some selection bias toward greater use of
asodilators in case of higher blood pressure, although we
lso often use vasodilators to wean people from inotropic or
ntra-aortic balloon pump support. The SNP was adminis-
ered intravenously by a continuous infusion at a dose of 10
o 400 g/min (without bolus) as needed to improve
emodynamics (Table 1). Titration of SNP dose was based
n achieving a target MAP of 65 to 70 mm Hg. The
itration was mainly done by nursing staff who are well
rained and experienced in the use of SNP and are able to
itrate drugs without continuous physician input. Once
AP goals were achieved (usually within 24 h), and
ptimal hemodynamic measures were maintained, SNP
nfusion was gradually weaned by maintaining the MAP at
5 to 70 mm Hg. Doses of neurohormonal antagonists
nd/or a combination of hydralazine and isosorbide dini-
rate were continued or up-titrated to guideline-
ecommended therapeutic doses. Titration of oral drugs
ollows standard protocols (Table 1) in our intensive care
nit, but the sequence of drugs was also at the attending
ardiologist’s discretion. The duration of infusions of intra-
enous agents in the intensive care unit varied widely, but
ypically lasted between 24 and 72 h. Standard patient
ducation materials and counseling were given to the patient
t the time of admission, and post-discharge follow-up was
rovided by a heart failure disease management clinic.
emodynamic assessment. Central venous pressure,
ight atrial pressure, systolic and diastolic blood pressure,
PAP, and PCWP were assessed on admission at end
xpiration with a balloon-tipped catheter at steady state
ith the patient in a supine position. Cardiac output was
etermined by calculation using the Fick equation
hrough sampling of a mixed central venous blood gas
aken in the pulmonary artery while assuming standard
etabolic rates. All initial measurements were performed
t the cardiac catheterization laboratory for consistency of
Abbreviations
and Acronyms
ADHF  acute
decompensated heart
failure
LV  left ventricle/
ventricular
MAP  mean systemic
arterial pressure
mPAP  mean pulmonary
arterial pressure
PCWP  pulmonary
capillary wedge pressure
SNP  sodium
nitroprussideesults reporting.
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Vasodilators for Low-Output Heart Failure July 15, 2008:200–7nd points. Three pre-specified end points were analyzed
nd compared between cases and control patients during
ollow-up: all-cause mortality, cardiac transplant, and first
eadmission for heart failure following discharge. A com-
ined end point of all-cause mortality and cardiac transplant
as also analyzed. The duration of total follow-up was
efined as the interval from the index right heart catheter-
zation on the day of admission to all-cause mortality or
ardiac transplant. Death was determined using data docu-
ented in the medical record and confirmed by surveying
he Social Security Death Index.
tatistical analysis. All data are expressed as mean 
tandard deviation for continuous variables and as a ratio for
ategorical data. Univariate and multivariate comparisons of
hese variables were performed between both treatment
roups for the different end points using SPSS for Win-
ows, Release 11.5 (SPSS Inc., Chicago, Illinois). A paired
nd unpaired t test for continuous data and chi-square or
isher exact test for categorical data was used for appropri-
te comparisons. All continuous variables were assessed for
ormal distribution and otherwise nonparametric tests were
mployed. The Cox proportional hazards regression model
as used to determine which variables were related signif-
cantly to the different end points during the follow-up
eriod. Variable selection in multivariable modeling was
ased on statistical significance of the univariate analysis.
tatistical significance was set at a 2-tailed probability level
tandard Medication Protocols for thelevel nd Clini Heart Failure Intensive Care Unit
Table 1 Standard Medication Protocols for theCleveland Clinic Heart Failure Intensive Care Unit
Sodium nitroprusside
Begin at 10 to 40 g/min (without bolus)
1 as tolerated to achieve desired hemodynamic goals, targeting MAP
65 to 70 mm Hg
Do not1 dose beyond 400 g/min
To wean off:2 infusion gradually as tolerated while maintaining MAP goals
and initiating/increasing oral vasodilators
Captopril
Incremental1 6.25¡12.5¡25¡50 mg
Begin at 6.25 to 12.5 mg orally
After 2 h, if initial dose tolerated,1 incrementally to next dose
After 2 h, if previous dose tolerated,1 incrementally to next dose
After 6 h, if previous dose tolerated, then 50 mg orally TID*
Isosorbide dinitrate
Begin 10 mg orally
After 2 h, if initial dose tolerated,1 to 20 mg
After 8 h, if 20 mg tolerated,1 to 40 mg
After 8 h, if 40 mg tolerated,1 to 60 mg
After 8 h, if 60 mg tolerated, then 60 mg orally TID*
Hydralazine
Begin 25 mg orally (or 10 mg if MAP is low or patient is in labile condition)
After 2 h, if initial dose tolerated,1 to 50 mg
After 6 h, if 50 mg tolerated,1 to 75 mg
After 6 h, if 75 mg tolerated,1 to 100 mg
After 6 h, if 100 mg tolerated, then 100 mg QID*
If previous dose is not tolerated, administer highest dose tolerated TID or QID.
MAP  mean arterial pressure; QID  4 times daily; TID  3 times daily.f 0.05.
n
cesults
aseline characteristics. A total of 175 patients fulfilled all
nclusion and exclusion criteria. Of these, 78 received SNP
uring their hospitalization (cases) and 97 did not receive
NP (control patients). Baseline clinical characteristics were
imilar among patients in the 2 study groups (Table 2).
ean intensive care and hospital duration was 3.5  1 and
 7 days, respectively, and was also similar between
roups. Brain natriuretic peptide measurements within 3
ays of admission were available in 32% of eligible subjects
nd were comparable between SNP-treated and non–SNP-
reated patients (median [25%, 75%]: 823 [577, 1,445] vs.
87 [571, 1,200] pg/ml).
emodynamic assessment. As shown in Table 3, the
atients treated with SNP presented with higher baseline
lling pressures and systemic and pulmonic vascular resis-
ance, while demonstrating a lower cardiac output and
ardiac index. Furthermore, the average mean arterial blood
ressure and systolic blood pressure at baseline was slightly
igher in the SNP cases than in control patients. Mean left
entricular (LV) ejection fraction, LV end-diastolic diame-
er, and severity of mitral regurgitation (assessed within 3
aseline Patient Characteristics
Table 2 Baseline Patient Characteristics
No Nitroprusside
(n  97)
Nitroprusside
(n  78) p Value
Demographics
Age (yrs) 55 11 55 11 NS
Men (%) 80 84 NS
Caucasian (%) 80 76 NS
African American (%) 19 22 NS
NYHA functional classification (%)
III 44 42 NS
IV 56 58 NS
Medical history (%)
Hypertension 77 70 NS
Hyperlipidemia 51 61 NS
Diabetes 28 27 NS
Smoking 47 55 NS
Previous CABG 28 36 NS
ICD 42 46 NS
CRT-D 16 13 NS
Etiology heart failure (%)
Ischemic 48 52 NS
Idiopathic dilated 39 39 NS
Valvular 8 5 NS
Other 5 3 NS
Serology
Hemoglobin (g/dl) 13.3 1.8 13.2 1.9 NS
BUN (mg/dl) 31 17 31 21 NS
Sodium (mmol/l) 136 4 137 4 NS
Serum creatine baseline (mg/dl) 1.4 0.5 1.3 0.5 NS
Serum creatine peak (mg/dl) 1.5 0.6 1.4 0.6 NS
Serum creatine discharge (mg/dl) 1.3 0.5 1.3 0.5 NS
alues are mean  SD or percentage.
BUN  blood urea nitrogen; CABG  coronary artery bypass graft; CRT-D  cardiac resynchro-
ization therapy with defibrillator; ICD  implantable cardioverter-defibrillator; NS  not signifi-
ant; NYHA  New York Heart Association.
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July 15, 2008:200–7 Vasodilators for Low-Output Heart Failureays of admission) were similar between the 2 groups. Of
ote, none of the patients had complications during inser-
ion of the pulmonary artery catheter, and none of the early
eaths could be directly attributed to catheter-related
omplications.
Hemodynamic assessments at the time of removal of the
ulmonary artery catheter were retrievable in 63% of the
tudy patients (Table 4). Missing data were due to incom-
lete recording of hemodynamic data in the charts and not
ttributable to futility in achieving hemodynamic targets.
hen compared with the initial hemodynamic assessment,
tatistically significant reduction of mPAP and increase in
ardiac index were achieved in both groups. However,
eduction in intracardiac pressures and the increase in
ardiac index were higher in the SNP-treated patients,
hough the overall mean hemodynamic measurements at the
ime of pulmonary artery catheter removal were similar
etween the 2 groups. Only cardiac index at this time was
igher in the SNP-treated patients (p  0.0156). In the
ame cohort of patients, we also retrieved the last MAP
aseline Hemodynamicnd Echocardi graph Variables
Table 3 Baseline Hemodynamicand Echocardiograph Variables
No Nitroprusside
(n  97)
Nitroprusside
(n  78) p Value
Hemodynamics
Sinus rhythm (%) 82 90 NS
Heart rate (beats/min) 86 20 81 18 NS
MAP (mm Hg) 82 11 86 11 0.01
Systolic BP (mm Hg) 106 14 110 15 0.05
CVP (mm Hg) 13 7 15 5 0.002
Systolic PAP (mm Hg) 51 15 63 14 0.001
Diastolic PAP (mm Hg) 26 9 32 7 0.001
PCWP (mm Hg) 24 8 29 7 0.001
CO (l/min) 3.6 0.8 3.2 0.7 0.002
CI (l/min/m2) 1.7 0.2 1.6 0.2 0.005
SVR (dynes/cm5) 1,601 419 1,846 567 0.002
PVR (Woods unit) 2.9 1.4 4.3 2.6 0.001
Echocardiography
EF (%) 15 7 15 5 NS
LVEDD (cm) 7 1 7 1 NS
MR (grade) 2 1 2 1 NS
alues are mean  SD or percentage.
BP  blood pressure; CI  cardiac index; CO  cardiac output; CVP  central venous pressure;
F  ejection fraction; LVEDD  left ventricular end-diastolic diameter; MAP  mean arterial
ressure; MR  mitral regurgitation; PAP  pulmonary arterial pressure; PCWP  pulmonary
apillary wedge pressure; PVR  pulmonary vascular resistance; SVR  systemic vascular
esistance.
emodynamics at Admission and Time of Pulmonary-Artery Cathetend Discharge From Ho p tal (MAP) Between Patients Who Did an
Table 4 Hemodynamics at Admission and Time of Pulmonary-Aand Discharge From Hospital (MAP) Between Patients
No Nitroprusside (n  49)
Admission Discharge
MAP (mm Hg) 82 12 74 8
Systolic PAP (mm Hg) 55 14 41 13
Diastolic PAP (mm Hg) 28 8 20 7
CI (l/min/m2) 1.6 0.2 2.4 0.5bbreviations as in Table 3.easured before discharge from the hospital after optimi-
ation with oral medications. A significant reduction in
AP was noticed in both cohorts, but overall MAP on
ischarge was similar between the 2 groups.
se of concomitant medications. As shown in Table 5,
dherence to optimal pharmacological therapy was high on
dmission and discharge and comparable between the 2
roups. Patients treated with SNP had higher use of
eta-adrenergic blockers on admission but not on discharge.
he percentage of patients treated with other agents during
ospitalization was similar in both groups. There was a
rend toward more use of inotropic agents at discharge in
atients not treated with SNP. The use of isosorbide
initrate and hydralazine separately and/or in combination
t the time of discharge was significantly higher in patients
reated with SNP. Use of oral vasodilators did not differ
etween Caucasian or African-American patients.
linical outcomes. Patients were followed for a median
uration of 25.7 months (379 patient-years) after the index
ight heart catheterization. No patient was lost during
ollow-up. There were 66 (38%) deaths and 60 (34%)
ardiac transplants. Primary outcome differences between 2
ohorts are shown in Table 6. Treatment with SNP during
ospitalization was associated with lower all-cause mortality
OR: 0.48; p  0.005; 95% confidence interval: 0.29 to
.80) and all-cause mortality/cardiac transplant (OR: 0.64;
 0.016; 95% confidence interval: 0.45 to 0.92) when
ompared with those not treated with SNP (Fig. 1). Both
arly and late all-cause mortality (defined as within or after
0 days after admission, respectively) were significantly lower
n the SNP-treated patients (both p values  0.01). The 2
reatment groups did not differ in cardiac transplant or heart
ailure rehospitalization rates. Median time to first heart failure
ehospitalization, cardiac transplant, and death were 8, 8.6, and
7.3 months, respectively, and did not differ significantly
etween the 2 cohorts. Use of SNP was not associated with an
ncreased use of inotropic therapy, nor did it contribute to
orsening renal dysfunction during hospitalization. Blood
ampling for thiocyanate toxicity was not routinely performed.
owever, no clinical signs of thiocyanate toxicity were noted in
ny patient receiving SNP.
To further validate our findings, we performed a
ubanalysis to include only the patients with a MAP of
85 mm Hg. In this cohort, use of SNP was still
ssociated with reduced all-cause mortality (p  0.0001)
moval (CI and PAP)Not Receive SNP During Hospitalization
Catheter Removal (CI and PAP)
Did and Did Not Receive SNP During Hospitalization
Nitroprusside (n  60)
p Value Admission Discharge p Value
0.001 87 12 74 11 0.001
0.001 65 13 42 12 0.001
0.001 33 7 19 6 0.001
0.001 1.6 0.2 2.6 0.5 0.001r Red Did
rtery
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Vasodilators for Low-Output Heart Failure July 15, 2008:200–7nd the combined end point of all-cause mortality plus
ardiac transplant (p  0.02). Also, if patients who
eceived an inotropic agent at discharge were excluded
rom the analysis, use of SNP was still associated with
educed all-cause mortality (p  0.003) and all-cause
ortality/cardiac transplant (p  0.03). Finally, although
he use of oral vasodilators was not associated with
mproved outcomes on univariate analysis, a successful
ransition from SNP to oral vasodilators at the time of
ischarge was associated with reduced all-cause mortality
se of Medication on Admission,uring Adm ssion, a d on Di charge
Table 5 Use of Medication on Admission,During Admission, and on Discharge
No Nitroprusside
(n  97)
Nitroprusside
(n  78) p Value
At admission (%)
Aspirin/clopidogrel 37 47 NS
Coumadin 55 44 NS
ACE-I/ARB 88 83 NS
Digoxin 70 68 NS
Beta-blockers 62 77 0.038
Spironolactone 37 35 NS
Loop diuretic 94 96 NS
Hydralazine 11 16 NS
Isosorbide dinitrate 28 26 NS
Statin 35 44 NS
Amiodarone 28 17 NS
Insulin 16 12 NS
During admission (%)
Nitroglycerine 1 5 NS
Dopamine 4 3 NS
Dobutamine 36 38 NS
Milrinone 37 25 NS
Dobutamine or milrinone 64 60 NS
Norepinephrine 1 0 NS
IABP 5 2 NS
Dobutamine or milrinone or IABP 67 61 NS
UF/dialysis 1 2 NS
At discharge (%)
Aspirin/clopidogrel 44 50 NS
Warfarin 50 37 NS
ACE-I/ARB 93 94 NS
Digoxin 72 73 NS
Beta-blockers 50 56 NS
Spironolactone 55 56 NS
Loop diuretic 92 96 NS
Hydralazine 28 54 0.001
ISDN 50 69 0.017
Hydralazine or ISDN 52 75 0.004
Hydralazine and ISDN 26 48 0.006
Statin 33 45 NS
Amiodarone 36 27 NS
Insulin 13 10 NS
Dobutamine 5 2 NS
Milrinone 7 3 NS
Dobutamine or milrinone 12 6 0.08
CE-I  angiotensin-converting enzyme inhibitor; ARB  angiotensin receptor blocker; IABP 
ntra-aortic balloon pump; ISDN  isosorbide dinitrate; NS  not significant; UF  ultrafiltration.ndependent from race (p  0.03).On univariate analysis, the absence of diabetes mellitus,
resence of beta-adrenergic blocker on admission, absence
f inotropic therapy during admission, lower creatinine
uring hospitalization and at discharge, and SNP use during
ospitalization were all associated with lower all-cause
ortality and all-cause mortality/cardiac transplant (all p 
.01). When these parameters were entered in a multivariate
odel for all-cause mortality, SNP use remained an inde-
endent predictor of survival (Table 7).
Figure 1 Clinical Outcomes According
to Use of Sodium Nitroprusside
Kaplan-Meier curves of all cause mortality (A) and the combined end point of
all-cause mortality and cardiac transplant (B) between patients who did and
did not receive intravenous sodium nitroprusside during hospitalization.
rimary Outcomes
Table 6 Primary Outcomes
Primary Outcome, % (n)
No Nitroprusside
(n  97)
Nitroprusside
(n  78) p Value
All-cause mortality 44 (43) 29 (23) 0.005
Cardiac transplant 35 (34) 33 (26) NS
All cause mortality 
cardiac transplant
79 (77) 63 (49) 0.016
Heart failure rehospitalization 56 (54) 60 (47) NS
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he key finding of our retrospective, nonrandomized case-
ontrol series is that vasodilator therapy with SNP, in an
n-patient setting of guideline recommended care, can be
afely administered to achieve hemodynamic improvement
n patients presenting with advanced low-output heart
ailure. Importantly, our observations suggest that the use of
NP according to a clinical protocol based on achieving a
arget MAP is associated with more hemodynamic im-
rovement that may facilitate the institution of a more
ggressive oral vasodilator regimen over standard neurohor-
onal antagonists at the time of discharge. Taken together,
he use of SNP was associated with significantly lower
ll-cause mortality and fewer clinical adverse events at
ong-term follow-up, irrespective of the use of inotropic
herapy or underlying renal function. These data under-
core the importance of assessing the potential for adding
asodilator therapy in patients with advanced low-output
eart failure yet seemingly reasonable mean arterial blood
ressure.
Despite clinical evidence suggesting hemodynamic and
oncordant clinical improvement, there have been limited
ata on the impact of continuous infusion of SNP on
ong-term outcomes in ADHF. Furthermore, SNP is infre-
uently used today for ADHF exacerbations especially
hen the cardiac output is significantly depressed and blood
ressure is marginal (17–19). The dual arteriolar and venous
ffects of SNP appear to contribute to the immediate
emodynamic response of the drug (20). Dilation of the
rterial resistance vessels reduces LV afterload and allows
he severely compromised LV to eject more blood. The
enodilator effect increases venous capacitance and reduces
ongestion. Both effects lead to an increase in cardiac output
n patients with heart failure and often reduce the basal
achycardia. We expect there is a reluctance of physicians to
se SNP in hospitalized ADHF patients with low cardiac
utput or marginal blood pressure. This stems from the
isguided belief that vasodilation could potentially be risky
f systemic vascular resistance is reduced without any com-
ensatory increase in cardiac output, leading to significant
ypotension and downward spiraling of detrimental hemo-
ynamic support. This concept, however, is an oversimpli-
cation of the usual cardiac hemodynamics observed, typi-
ally in patients with severe LV systolic dysfunction with
redictors of All-Causeortality on Multivariate Analysis
Table 7 Predictors of All-CauseMortality on Multivariate Analysis
Hazard
Ratio
95% Confidence
Interval p Value
Sodium nitroprusside 0.54 0.33–0.88 0.015
Beta-blocker 0.48 0.29–0.78 0.03
Diabetes mellitus 1.13 0.62–2.07 0.7
Inotropic agent 2 1.36–3.6 0.01
Creatinine 2.16 1.56–3.24 0.001ncreased ventricular volumes. The substantial improvement Hn cardiac output more than offsets any fall in blood pressure
nder most circumstances. As a result, a reduction in
fterload or wall stress during SNP administration usually
eads to a marked increase in cardiac output, preventing the
evelopment of significant hypotension. Our data corrobo-
ate this hypothesis, as we observed that the SNP-treated
atients had a statistically greater increase in cardiac index
ithout substantial reduction in MAP when compared with
he non–SNP-treated control cohort.
Alternative treatment strategies in these critically ill
ospitalized ADHF patients include intravenous infusion of
notropic therapy. These drugs can lead to symptomatic and
emodynamic improvement, but at the cost of increased risk
or ischemic events, tachyarrhythmias, and long-term mor-
ality (14,21). In contrast to inotropic therapies, SNP is
nergetically neutral and reduces myocardial oxygen con-
umption by a reduction in LV wall tension. Furthermore,
ncreased coronary perfusion pressure via coronary vasodi-
ation can lead to a protective effect on the already compro-
ised myocytes (22–24). It is likely that SNP improves
ardiac output but not at the expense of increased myocar-
ial oxygen demand.
The presence of a low cardiac output and elevated
ntracardiac filling pressures in the setting of ADHF rep-
esents a very high-risk individual, and the ability to safely
dd SNP to standard optimal medical therapy is of great
eassurance. It is important to emphasize that the profile of
ur patient population has important differences from re-
ent large-scale clinical registries such as ADHERE (Acute
ecompensated Heart Failure National Registry) and from
he recently published ESCAPE (Evaluation Study of
ongestive Heart Failure and Pulmonary Artery Catheter-
zation Effectiveness) trial (12,25). With an annual mortal-
ty plus cardiac transplant rate as high as 50%, our patient
ohort likely has far more advanced disease than those in the
DHERE registry or even the ESCAPE trial. Although
he ESCAPE trial has raised concerns about the risk-benefit
atio of routine invasive hemodynamic monitoring in pa-
ients hospitalized with ADHF, our study at least lends
ome credit to using invasive monitoring when adding
ntravenous vasoactive drug therapy in this advanced heart
ailure population. Of particular importance, we observed
o greater incidence of hypotension or worsening renal
ysfunction during hospitalization. Furthermore, there was
trend toward less use of inotropic drugs in the SNP-
reated group. However, because selection bias may have
ntered the decision to use SNP, this difference might also
e the result of the nontreated SNP patients being “sicker.”
Recent reports have also highlighted the important prog-
ostic value of systemic blood pressure in ADHF (12,26).
he use of SNP versus inotropic agents may have been
iased in part because of a higher MAP or systolic blood
ressures at baseline, a known predictor of better outcomes
n the setting of ADHF. Additionally, patients with higher
lood pressure are assumed to be more tolerant of SNP.
owever, as we excluded patients with low MAPs, and the
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Vasodilators for Low-Output Heart Failure July 15, 2008:200–7resence of equivalent post-treatment hemodynamics and
APs between both patient groups, our findings suggest
hat the administration of vasodilator therapy primarily
argets any potentially “reversible” contributions of hemo-
ynamic alteration. Also, subanalysis of the patients with
AP 85 mm Hg still demonstrated a better outcome in
he SNP-treated group, thus suggesting that low blood
ressure per se should not necessarily dissuade physicians
rom using SNP.
The early and continuous separation of the mortality
urves for the 2 cohorts implies a continued and increasing
enefit of vasodilator therapy throughout the follow-up
eriod. We hypothesize that this is secondary to the ability
o establish an early optimal hemodynamic balance with
NP, allowing the institution of longer-term oral vasodila-
or therapy bridged by SNP titration. Thus, use of early
ntravenous and late oral vasodilators exerts an improved
hort-term hemodynamic benefit and a long-term survival
enefit. The fact that this benefit was observed in patients
lready treated with maximal neurohormonal blockade lends
redence to the suggestion that the combination of agents is
xerting an effect via mechanisms incremental to neurohor-
onal antagonism. Indeed oral vasodilators have been
roven to enhance nitric oxide bioavailability (27), myocar-
ial metabolism (28) and energy regulation (29), to have
otent antioxidant effects (30), and reduce LV hypertrophy
31) and remodeling (32), in addition to significant mor-
idity and mortality benefits when used in African Ameri-
ans with advanced heart failure (33). Our results provide
dditional support for the beneficial use of these vasodilators
hydralazine and nitrates) in patients with advanced heart
ailure, independent of race (33–35).
tudy limitations. Obvious limitations inherent to the
etrospective study design should be considered when find-
ngs are interpreted. Comprehensive follow-up, review of
vents, and centralized adjudication minimized the poten-
ial for missed or misclassified outcomes. However, selection
ias probably entered the decision to treat or not treat
atients with SNP, which trended toward the use of SNP in
atients with higher systemic, right- and left-sided filling
ressures, and lower cardiac output. This may suggest that
he SNP group was more hemodynamically compromised,
tipping the scales” in favor of standard therapy. Also, only
ne-half of the patients had implantable cardioverter defi-
rillator or cardiac resynchronization therapy with defibril-
ator because widespread use of the devices only started after
002. The mechanism of death could not be ascertained,
ut other studies of advanced heart failure suggest that a
ajority of patients die of progressive pump failure (36).
ccurate estimates about duration of vasoactive therapies
dministered, medication doses, and how many patients
chieved hemodynamic goals in both treatment arms could
ot be retrieved due to logistic limitations. It should also be
mphasized that our patient population was younger than
he overall heart failure population thereby explaining the
igher cardiac transplant rate. Lastly, our single-center dataas achieved while patients were hospitalized in a special-
zed heart failure intensive care unit, which included med-
cal and nursing staff that are experienced in the use of SNP.
ecognizing all the aforementioned limitations, we believe
hat the information provided in this study is a well-
alanced description of our long-standing, in general, pos-
tive experience with use of SNP in advanced decompen-
ated heart failure patients. Together with the ongoing
ontroversy with another vasodilator, nesiritide (37), and
otential detrimental effects of inotropic agents, we hope
ur data will provide some insights into the potential for
eviving an age-old concept of a vasodilator-based approach
o low cardiac output in carefully selected patients who may
olerate such strategy. Careful interpretation of our findings
hould be based on the applicability of our protocols, and
urther studies are needed to examine the safety and efficacy
f SNP-based intensive medical therapy in this vulnerable
opulation.
onclusions
n our single-center study, we demonstrated that intrave-
ous SNP could be safely administered in selected patients
dmitted with advanced low-output heart failure to achieve
n optimal hemodynamic profile. The use of SNP as part of
ntensive medical therapy and the transition to oral vasodi-
ators in patients already treated with neurohormonal an-
agonists was associated with improved long-term clinical
utcomes irrespective of inotropic drug usage or renal
ysfunction during admission.
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